Addressing Delayed Hospital Discharges for Patients With Intellectual and Developmental Disabilities and a Mental Illness.

Psychiatr Serv

Centre for Addiction and Mental Health, Toronto (Selick, Volpe, Lunsky); private consultant, Toronto (Morris); Department of Psychiatry, University of Toronto, Toronto (Lunsky).

Published: September 2024

AI Article Synopsis

  • * This delay happens even when patients are ready to go home, often because there aren’t enough places for them to go afterward.
  • * In Canada, new guidelines were created to help these patients transition better, focusing on teamwork between hospitals, families, and community health providers.

Article Abstract

Adults with intellectual and developmental disabilities (IDD) who also have a co-occurring mental illness are almost five times as likely to experience a delayed hospital discharge as adults with mental illness only. Such delays occur when a patient no longer requires hospital-level care but cannot be discharged, often because of a lack of appropriate postdischarge settings. Delayed discharges contribute to poor patient outcomes, increased system costs, and delayed access to care. Recently, practice guidance was developed in Canada, identifying 10 components of successful transitions for this population. Core to this guidance is a patient-centered, cross-sectoral approach, including the patient, family, hospital team, community health care providers, and IDD providers.

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ps.20240177DOI Listing

Publication Analysis

Top Keywords

mental illness
12
delayed hospital
8
intellectual developmental
8
developmental disabilities
8
addressing delayed
4
hospital discharges
4
discharges patients
4
patients intellectual
4
disabilities mental
4
illness adults
4

Similar Publications

Implementation of stop smoking support by mental healthcare professionals: cross-sectional analysis of why nothing much happens.

Discov Ment Health

January 2025

Public Health and Primary Care, Leiden University Medical Center, Hippocratespad 21, PO Box 9600, 2300 RC, Leiden, The Netherlands.

Smoking is highly prevalent and persistent among people with mental illness, but implementation of smoking cessation care by mental healthcare professionals (MHCPs) is lagging behind. This study took a broad approach to understanding implementation of stop smoking support (SSS) by MHCPs (N = 220 for main analyses), incorporating background characteristics, psychosocial factors, client factors, and organizational/environmental factors. Variable selection was based on previous work and the Consolidated Framework for Implementation Research.

View Article and Find Full Text PDF

Purpose: This study aimed to investigate the prevalence and sociodemographic determinants of major depressive disorder (MDD) and generalized anxiety disorder (GAD) among Mozambican youth aged 15-24 years, as well as their help-seeking behaviors.

Methods: Data from 8,154 youth participants in the 2022-23 Mozambique Demographic Health Survey were analyzed. MDD and GAD were assessed using the PHQ-9 and GAD-7 scales, respectively.

View Article and Find Full Text PDF

Background: Conventional medical management, while essential, cannot address all multifaceted consequences of Parkinson's disease (PD). This pilot study explores the potential of a co-designed creative arts therapy on health-related quality of life, well-being, and pertinent non-motor symptoms.

Methods: We conducted an exploratory pilot study with a pre-post design using validated questionnaires.

View Article and Find Full Text PDF

Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer's disease diagnosis in a memory clinic cohort.

J Neurol

January 2025

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Fundació de Recerca Clínic - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villaroel 170, 08036, Barcelona, Spain.

Plasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer's disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have been performed in research cohorts, limiting their generalizability. We studied plasma p-tau217 and p-tau181 for CSF Aβ status discrimination in a cohort of consecutive patients attending an academic memory clinic in Spain (July 2019-June 2024). All patients had CSF AD biomarkers performed as part of their routine clinical assessment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!